SB

SHASHIKANT BHANDARI

All India Shri Shivaji Memorial Society's College of Pharmacy, All India Shri Shivaji Memorial Society College of Pharmacy, AISSMS COLLEGE OF PHARMACY pune

ORCID iD 0000-0001-9661-9921
Follow

About

SHORT RESUME OF PI DR. SHASHIKANT V BHANDARI

Name of PI Dr. Shashikant V, bhandari
Date of Birth 07/10/1974
Domain Expertise Molecular Modelling, ant-cancer, anti-tubercular, synthesis, Pharmaceutical chemistry
Number of articles in pubmed (past 10 years) 26
H-Index 13
Fellow of Academies Elsevier Academy, Netherland, Europe,
Member QSAR.ORG society.

Details of Publication related to the proposal:
Details of Patents: Indian Patent Office
1. Patent Title:SUBSTITUTED THIAZOLE COMPOUNDS AS ANTICANCER AGENTS
Applicants:Mrs. Sonali Sandeep Shinde, Dr. Aniket Sarkate, Dr. Dattatraya Pansare, Dr. Smita Pawar, Mr. Rajesh Yadala, Dr. Pravin Wakte, Dr. Shashikant Bhandari.Mr. Kalusing Padvi
Patent No.:544207 (Application no 202321072475)
Status:Granted in Force
2. Patent Title: Substituted diazole compounds as anticancer agents
Applicants: Shashikant V. Bhandari, Shital Patil
Patent No.: 202321039450
Status: Office Action
3. Patent Title: Substituted 3,5-Diaryl Pyrazoles compounds as anticancer agents
Applicants: Shashikant V. Bhandari, Aniket P. Sarkate
Patent No.: 20212100130 (dated 07/01/2021)
Status: Office Action
4. Patent Title: Substituted N-Phenyl 2,2–dichloro acetamide compounds as anticancer agents
Applicants: Shashikant V. Bhandari, Aniket P. Sarkate
Patent No.: 20212100002076 (dated 16/01/2021)
Status: Office Action


Title Impact factor of Journal Name of policy/programme/ protocol document or patent/commercialization of products where cited.
Inamdar, Poonam R, et al. “Applications of Samarium Complexes as Cytotoxic, Bioimaging and DNA Interacting Agents: A Comprehensive Review.” Reviews in Inorganic Chemistry, vol. 44, no. 3, 8 Mar. 2024, pp. 377–383, https://doi.org/10.1515/revic-2023-0026. Accessed 7 Dec. 2024.
4.1
Shinde, Sonali S, et al. “Computational and Synthetic Approach with Biological Evaluation of Substituted Thiazole Derivatives as Small Molecule L858R/T790M/C797S Triple Mutant EGFR Inhibitors Targeting Resistance in Non-Small Cell Lung Cancer (NSCLC).” Research Square (Research Square), 19 Feb. 2024, scite.ai/reports/computational-and-synthetic-approach-with-K6mdYdnp, https://doi.org/10.21203/rs.3.rs-3957730/v1. Accessed 7 Dec. 2024. Research square
Gore, V A, et al. “Synthesis, Characterization of Novel Thiazole Hydrazine Derivatives, and Inhibitory Action against the VEGFR-2.” Russian Journal of Bioorganic Chemistry, vol. 50, no. 2, 1 Apr. 2024, pp. 345–353, discovery.researcher.life/article/synthesis-characterization-of-novel-thiazole-hydrazine-derivatives-and-inhibitory-action-against-the-vegfr-2/60e2d1b797be3fc08b0bbb0bd74d6b33, https://doi.org/10.1134/s1068162024020067. Accessed 7 Dec. 2024. 1.1
Patil, Shital M, et al. “Molecular Modeling of Some 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors for the Treatment of Cancer.” Letters in Drug Design & Discovery, vol. 21, no. 10, 10 Apr. 2023, pp. 1694–1706, www.eurekaselect.com/article/130805, https://doi.org/10.2174/1570180820666230410083544. Accessed 7 Dec. 2024. 1.2
Tiwari, Shailee V., et al. “Appraisal and Synthesis of Novel Indole-Thiazole Derivatives as Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors against Resistance Mutation for Lung Cancer Treatment.” Results in Chemistry, vol. 11, 30 Aug. 2024, p. 101760, www.sciencedirect.com/science/article/pii/S2211715624004569, https://doi.org/10.1016/j.rechem.2024.101760. Impact factor 2.3
Bhandari, Shashikant V., et al. “Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono‐Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.” Chemistry & Biodiversity, vol. 20, no. 11, 26 Oct. 2023, https://doi.org/10.1002/cbdv.202301081. Accessed 27 Oct. 2024. 2.7
Patil, Shital M., and Shashikant V. Bhandari. “Optimization of Pharmacophore of Novel Hybrid Nucleus of 1,3,4-Oxadiazole-Chalcone Using Literature Findings and In-Silico Approach as EGFR Inhibitor.” Letters in Drug Design & Discovery, vol. 19, 14 Apr. 2022, https://doi.org/10.2174/1570180819666220414102310. Accessed 8 July 2022. Impact factor 1.15)
Patil, Shital, and Shashikant Bhandari. “A Review: Discovering 1,3,4-Oxadiazole and Chalcone Nucleus for Cytotoxicity
/ EGFR Inhibitory Anticancer Activity.” Mini-Reviews in Medicinal Chemistry, vol. 22, no. 5, Mar. 2022, pp. 805–820, https://doi.org/10.2174/1389557521666210902160644. Accessed 14 Nov. 2022. 3.86

Experience as Investigator:

SNo Title Role Funding Agentcy Amount Status

1 Design of Potential anti-inflammatory agents using molecular modeling studies. PI Minor/ S.P.P.University, Pune 1,50,000/ Completed, audited and Utilization certificate submitted.
2 Design of Potential anti-viral agents using molecular modeling studies. PI Minor/ S.P.P.Univ. Pune 1,95,000/-
3 Design of Potential anti-tubercular agents using molecular modeling studies. PI Minor/ S.P.P.Univ. Pune 2,20,000/-
Completed, audited and Utilization certificate submitted
4 To establish and implement the Entrepreneurship Development Cell activi

Employment

  • All India Shri Shivaji Memorial Society's College of Pharmacy RESEARCHER ADVISOR FOR PG AND Ph.D./PROFESSOR
    1999 - Present
  • All India Shri Shivaji Memorial Society College of Pharmacy RESEARCHER ADVISOR FOR PG AND Ph.D./PROFESSOR
    1999 - 2025
  • All India Shri Shivaji Memorial Society College of Pharmacy Professor
    1999 - 2025

Education

  • AISSMS COLLEGE OF PHARMACY pune M.pharm.Ph.D.
    2003 - 2010
  • AISSMS COLLEGE OF PHARMACY pune M.pharm.Ph.D.
    2003 - 2010

Projects & Funding

Projects & funding information is unavailable.

Publications (25)